[Skip to Content]
[Skip to Content Landing]
Views 2,607
Citations 0
Editorial
July 2, 2014

Reconsideration of Age as a Contraindication for Curative Therapy of Sickle Cell Disease

Author Affiliations
  • 1Program in Occupational Therapy, Division of Pediatric Hematology-Oncology, Department of Pediatrics, Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri
  • 2Division of Oncology, Department of Medicine, Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri
JAMA. 2014;312(1):33-34. doi:10.1001/jama.2014.7193

Approximately 100 000 Americans, primarily African Americans, have sickle cell disease.1 Worldwide, the burden of this disease is much greater with an estimated 300 000 affected infants born.2 A single nucleotide substitution causes the autosomal recessive disease: valine replaces glutamic acid in the sixth position of the β-globin protein. Despite the discovery of the etiology of sickle cell disease more than 60 years ago,3 little progress has been achieved in the treatment or cure of this chronic disease.

First Page Preview View Large
First page PDF preview
First page PDF preview
×